2248046-39-9
Chemical Structure
FCN-338
Synonym(s): LOXO-338
- No. CAS: 2248046-39-9
- Formula:C48H48ClN7O7S
- Molecular Weight:902.46
IUPAC Name: (S)-2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-N-((3-benzyl-5-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)sulfonyl)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzamide
InChIKey: NBXDZQVXLFWIJW-BHVANESWSA-N
SMILES: ClC1=CC=C(C=C1)C(CC(C)(CC2)C)=C2CN3CCN(C4=CC=C(C(NS(=O)(C5=CC(OC6)=C(C([N+]([O-])=O)=C5)N[C@H]6CC7=CC=CC=C7)=O)=O)C(OC8=CN=C9NC=CC9=C8)=C4)CC3
Biological Activity: FCN-338 (LOXO-338) is an orally active and selective BCL2 inhibitor with an IC50 of 4.5 nM. FCN-338 also exhibits certain inhibitory activity against Bcl-xL, with an IC50 of 49 nM. FCN-338 blocks the BCL2-BAK/BIM interaction and promotes apoptosis in BCL2-dependent hematologic tumor cells. FCN-338 can be used for research on lymphoma and leukemia[1][2][3].
| Referencia número | Nombre del producto | Pureza | Descripciòn | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
FCN-338 | 99.33% | FCN-338 (LOXO-338) is an orally active and selective BCL2 inhibitor with an IC50 of 4.5 nM. FCN-338 also exhibits certain inhibitory activity against Bcl-xL, with an IC50 of 49 nM. FCN-338 blocks the BCL2-BAK/BIM interaction and promotes apoptosis in BCL2-dependent hematologic tumor cells. FCN-338 can be used for research on lymphoma and leukemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Vogler M, et al. The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy. Signal transduction and targeted therapy. 2025 Mar 21;10(1):91. [Content Brief]
- [2]. Brandhuber B, et al. Abstract 1258: Preclinical characterization of LOXO-338, a novel, oral and selective BCL2 inhibitor. Cancer Res. 2021;81(13 Suppl):1258.
- [3]. Kwiatek M, et al. A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies. Clinical lymphoma, myeloma & leukemia. 2025 Jul;25(7):512-519.
